Arthritis/rheumatic disorders:
Indications for: KINERET
To reduce signs/symptoms and slow progression of structural damage in moderately to severely active rheumatoid arthritis (RA) that failed DMARD(s), as monotherapy or with DMARDs other than TNF blockers.
Adult Dosage:
≥18yrs: 100mg SC once daily. Severe renal impairment or ESRD (CrCl <30mL/min): may consider every other day dosing.
Children Dosage:
<18yrs: not recommended.
KINERET Contraindications:
Hypersensitivity to E. coli-derived proteins.
KINERET Warnings/Precautions:
Increased risk of serious infections; discontinue if develop in RA patients; consider risk vs. benefit in NOMID and DIRA patients. Active infections: do not initiate. Chronic infections (eg, tuberculosis). Asthma. Immunosuppression. Malignancies. Discontinue if severe hypersensitivity reaction occurs. Increased risk of allergic reactions in DIRA patients; monitor closely esp in the first several weeks after initiation; consider discontinuing if severe allergic reaction occurs. Monitor neutrophil count at baseline, monthly for first 3 months, then every 3 months for up to 1 year. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
KINERET Classification:
Interleukin-1 (IL-1) blocker.
KINERET Interactions:
Concomitant TNF blockers; not recommended. Avoid concurrent live vaccines.
Adverse Reactions:
Inj site reactions, upper RTI, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain, pyrexia, gastroenteritis; infections, neutropenia.
How Supplied:
Single-dose syringe—7, 28
Miscellaneous immune disorders:
Indications for: KINERET
Neonatal-Onset Multisystem Inflammatory Disease (NOMID). Deficiency of interleukin-1 receptor antagonist (DIRA).
Adult Dosage:
≥18yrs: not applicable.
Children Dosage:
<18yrs: Initially 1–2mg/kg SC daily; may adjust by increments of 0.5–1mg/kg; max 8mg/kg/day. For NOMID: usually give once daily, but dose may be split into twice daily administration. Severe renal impairment or ESRD (CrCl <30mL/min): may consider every other day dosing.
KINERET Contraindications:
Hypersensitivity to E. coli-derived proteins.
KINERET Warnings/Precautions:
Increased risk of serious infections; discontinue if develop in RA patients; consider risk vs. benefit in NOMID and DIRA patients. Active infections: do not initiate. Chronic infections (eg, tuberculosis). Asthma. Immunosuppression. Malignancies. Discontinue if severe hypersensitivity reaction occurs. Increased risk of allergic reactions in DIRA patients; monitor closely esp in the first several weeks after initiation; consider discontinuing if severe allergic reaction occurs. Monitor neutrophil count at baseline, monthly for first 3 months, then every 3 months for up to 1 year. Renal or hepatic impairment. Elderly. Pregnancy. Nursing mothers.
KINERET Classification:
Interleukin-1 (IL-1) blocker.
KINERET Interactions:
Concomitant TNF blockers; not recommended. Avoid concurrent live vaccines.
Adverse Reactions:
Inj site reactions, upper RTI, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain, pyrexia, gastroenteritis; infections, neutropenia.
How Supplied:
Single-dose syringe—7, 28
